Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ICML 2021

Latest Updates

View all
7:00
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma
Andrés Ferreri • 9 Jun 2021
2:39
Advances in lymphoma imaging
Sally Barrington • 9 Jun 2021
1:55
PET scans in NHL
Sally Barrington • 9 Jun 2021
4:50
PET-adapted treatment in PMBCL
Eliza Hawkes • 9 Jun 2021

Non-Hodgkin Lymphoma

View all
3:44
ELARA: tisa-cel in R/R follicular lymphoma
Nathan Fowler • 18 Jun 2021
7:00
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma
Andrés Ferreri • 9 Jun 2021
1:44
Genetics and biomarkers in diagnosing and treating lymphoma
Ash Alizadeh • 17 Jun 2021
4:50
PET-adapted treatment in PMBCL
Eliza Hawkes • 9 Jun 2021

CLL

View all
3:56
TRANSCEND-CLL-004: liso-cel in CLL
William Wierda • 18 Jun 2021
1:18
Pirtobrutinib: The next generation of BTK inhibitors
Barbara Eichhorst • 8 Jun 2021

Immuno-Oncology

View all
5:35
MCL0208: identification of novel genomic prognostic factors
Simone Ferrero • 16 Jun 2021
1:56
The future of CAR T-cell therapies in hematologic malignancies
Nathan Fowler • 18 Jun 2021
Visit the Lymphoma Channel for the latest updates from leading experts

The content of VJHemOnc is intended for healthcare professionals